515 results on '"Amer M. Zeidan"'
Search Results
2. Patients’ perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms
3. Clonal cytopenia of undetermined significance: definitions, risk and therapeutic targets
4. Integrated genetic, epigenetic, and immune landscape of mutant AML and higher risk MDS treated with azacitidine
5. Prognostic impact of ‘multi-hit’ versus ‘single hit’ TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases
6. Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
7. Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country
8. Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia
9. S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY
10. S165: CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
11. S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
12. S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)
13. P489: PROGNOSTIC IMPACT OF 'MULTI-HIT' VERSUS 'SINGLE-HIT' TP53 MUTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: RESULTS FROM THE CONSORTIUM ON MYELOID MALIGNANCIES AND NEOPLASTIC DISEASES (COMMAND)
14. P541: REAL-WORLD USE OF VENETOCLAX (VEN) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) IN A US REAL-WORLD EVIDENCE DATABASE (COTA)
15. P745: MULTI-CENTER PHASE IB TRIAL OF THE HISTONE DEACTYLASE INHIBITOR ENTINOSTAT + PEMBROLIZUMAB IN MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA REFRACTORY TO HYPOMETHYLATING AGENTS
16. P732: ANALYSIS OF PATIENT-REPORTED FATIGUE IN IMERGE PH3 TRIAL OF IMETELSTAT VS PLACEBO IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES R/R TO ERYTHROPOIESIS STIMULATING AGENTS
17. P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
18. P741: PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
19. P735: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES
20. PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
21. PB2010: FIRST-LINE TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES: A GLOBAL, RETROSPECTIVE OBSERVATIONAL COHORT STUDY
22. How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms
23. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis
24. The Current Understanding of and Treatment Paradigm for Newly-Diagnosed TP53-Mutated Acute Myeloid Leukemia
25. A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome
26. What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach
27. Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States
28. Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
29. Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?
30. Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis
31. Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis
32. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
33. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
34. BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?
35. Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
36. Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
37. Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?
38. Case Report of a Patient with Left Ventricular Assistance Device Undergoing Chemotherapy for a New Diagnosis of Lung Cancer
39. Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment
40. Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment
41. Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms
42. Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms
43. Epidemiology and Pathogenesis of Myelodysplastic Syndrome
44. Impact of Prophylactic Antibacterials on Coagulation Profiles and Bleeding in Patients with Acute Myeloid Leukemia/Myelodysplastic Syndrome
45. STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2
46. Considerations for Drug Development in Myelodysplastic Syndromes
47. Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States
48. An overview of novel therapies in advanced clinical testing for acute myeloid leukemia
49. Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study
50. Advances in myelodysplastic syndromes: promising novel agents and combination strategies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.